Success Metrics

Clinical Success Rate
86.7%

Based on 52 completed trials

Completion Rate
87%(52/60)
Active Trials
37(27%)
Results Posted
19%(10 trials)
Terminated
8(6%)

Phase Distribution

Ph phase_1
3
2%
Ph early_phase_1
1
1%
Ph not_applicable
39
28%
Ph phase_2
3
2%
Ph phase_4
5
4%

Phase Distribution

4

Early Stage

3

Mid Stage

5

Late Stage

Phase Distribution51 total trials
Early Phase 1First-in-human
1(2.0%)
Phase 1Safety & dosage
3(5.9%)
Phase 2Efficacy & side effects
3(5.9%)
Phase 4Post-market surveillance
5(9.8%)
N/ANon-phased studies
39(76.5%)

Highest Phase Reached

Phase 4

Trial Status & Enrollment

Completion Rate

83.9%

52 of 62 finished

Non-Completion Rate

16.1%

10 ended early

Currently Active

37

trials recruiting

Total Trials

137

all time

Status Distribution
Active(51)
Completed(52)
Terminated(10)
Other(24)

Detailed Status

Completed52
Recruiting29
unknown24
Not yet recruiting13
Terminated8
Active, not recruiting8

Development Timeline

Analytics

Development Status

Total Trials
137
Active
37
Success Rate
86.7%
Most Advanced
Phase 4

Trials by Phase

Early Phase 11 (2.0%)
Phase 13 (5.9%)
Phase 23 (5.9%)
Phase 45 (9.8%)
N/A39 (76.5%)

Trials by Status

withdrawn21%
unknown2418%
enrolling_by_invitation11%
terminated86%
active_not_recruiting86%
completed5238%
recruiting2921%
not_yet_recruiting139%

Recent Activity

Clinical Trials (137)

Showing 20 of 137 trialsScroll for more
NCT05487248Not Applicable

A Study of On-treatment ctDNA Changes in Chemo-refractory Colorectal Cancer Patients

Active Not Recruiting
NCT07499921Not Applicable

Clinical and BIOgical Analyses of RECtal Tumors

Not Yet Recruiting
NCT07455136

A Study to Develop a Blood-based Test for Aiding the Diagnosis/Prognosis of Traumatic Brain Injury in Adults and for Monitoring the Development of Secondary Events in Patients Diagnosed With Traumatic Brain Injury

Recruiting
NCT03595813Not Applicable

Identifying Immune-related Biomarkers to Predict the Efficacy of Cancer Immunotherapy

Completed
NCT04165798

KEYMAKER-U01 Umbrella Master Study: Studies of Investigational Agents With Either Pembrolizumab (MK-3475) Alone or With Pembrolizumab PLUS Chemotherapy in Participants With Non-small Cell Lung Cancer (NSCLC) (MK-3475-U01/KEYMAKER-U01)

Recruiting
NCT07436637Not Applicable

Guardant Shield Colorectal Cancer Screening

Not Yet Recruiting
NCT07516392Not Applicable

Study of a Polygenic Risk Score to Predict the Risk of Pancreatic Ductal Adenocarcinoma

Not Yet Recruiting
NCT07054346Phase 1

Comparison of 177Lu-PSMA-617 and 225Ac-PSMA-617

Recruiting
NCT07499739Phase 4

Mpox Biology, Outcome, Transmission and Epidemiology - Tracking the Immune Response After mpoX vaCcination (MBOTE-TRAXX): Clinical Study to Monitor the Immunological Response Following Mpox Vaccination in the City of Kinshasa, Democratic Republic of the Congo

Not Yet Recruiting
NCT07201636Not Applicable

Natural History Study for Patients With Nemaline Myopathy in Belgium

Not Yet Recruiting
NCT06695494

Enabling Genomic Testing in Cancer of Unknown Primary

Recruiting
NCT05306288

CASCADE-LUNG: Cancer Screening Assay Using DELFI; A Clinical Validation Study in Lung

Active Not Recruiting
NCT03922776Not Applicable

Phenotypic Characterization Tumor-infiltrating Lymphocytes at Diagnosis and After Chemotherapy in Ovarian Cancer

Terminated
NCT07046260

Prospective Study to Assess a Diagnostic Aid for Cancer

Recruiting
NCT04857528

Detecting HPV DNA in Anal and Cervical Cancers

Recruiting
NCT07243067

Tumor-Derived Extracellular Vesicles for Noninvasive Molecular Classification of Kidney Cancer

Not Yet Recruiting
NCT07405515Not Applicable

Pathophysiology of Dysautonomia and Postural Tachycardia Syndrome (POTS) in Post-viral Syndromes and COVID-19

Active Not Recruiting
NCT05687188

Evaluating Obesity-Mediated Mechanisms of Pancreatic Carcinogenesis in Minority Populations

Recruiting
NCT05328037

Study on the Association Between Vitamin C Deficiency and Diarrhea in Children

Completed
NCT04410432

Immune Response and Risk of Serious Infection to SARS-Cov2

Completed

Drug Details

Intervention Type
OTHER
Total Trials
137